ANTICORPS HUMANISÉS DIRIGÉS CONTRE RÉCEPTEUR 4 DES CHIMIOKINES CC (CCR4) ET LEURS PROCÉDÉS D'UTILISATION

• 收藏
• 分享

专利权人:

Dana Farber Cancer Institute; Inc.

发明人:

申请号：

EP20153701.6

公开号：

EP3699196A1

申请日:

2015.10.06

申请国别(地区):

EP

年份:

2020

代理人:

摘要：

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4- IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/